LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Pre-Mkt 08-06 07:13:01 EDT

1.00

+0.04

+4.25%

盘前1.02

+0.02+1.56%

07:00 EDT

High1.04	Low0.9604	Vol2.38M
Open0.9738	D1 Closing0.9592	Amplitude8.30%
Mkt Cap203.07M	Tradable Cap152.29M	Total Shares203.07M
T/O2.40M	T/O Rate1.56%	Tradable Shares152.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1,"timestamp":1785960000000,"preClose":0.9592,"halted":0,"volume":2376412,"hourTrading":{"tag":"盘前","latestPrice":1.0156,"preClose":1,"latestTime":"07:00 EDT","volume":4,"amount":4.0624,"timestamp":1786014005256,"change":0.0156,"changeRate":0.0156,"amplitude":0},"delay":0,"changeRate":0.04253544620517092,"floatShares":152289743,"shares":203066783,"eps":-0.485748,"marketStatus":"Pre-Mkt","change":0.0408,"latestTime":"08-06 07:13:01 EDT","open":0.9738,"high":1.04,"low":0.9604,"amount":2398666.3854563995,"amplitude":0.082986,"askPrice":1.11,"askSize":100,"bidPrice":0.98,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.485748,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786023000000},"marketStatusCode":1,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":1.0156,"preClose":1,"latestTime":"07:00 EDT","volume":4,"amount":4.0624,"timestamp":1786014005256,"change":0.0156,"changeRate":0.0156,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.987,"preClose":1,"latestTime":"19:59 EDT","volume":92008,"amount":92658.5271,"timestamp":1785974359198,"change":-0.013,"changeRate":-0.013,"amplitude":0.0443},"volumeRatio":2.0613291777972726},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2657176542","title":"PAVmed Unit Lucid Diagnostics Wins Concert Commercial Coverage Policy for EsoGuard Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2657176542","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657176542?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:48","pubTimestamp":1785934132,"startTime":"0","endTime":"0","summary":"PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard testPAVmed subsidiary Lucid Diagnostics won a positive Concert commercial coverage policy for its EsoGuard esophageal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL3rXdRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542190","title":"Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for Its Esoguard® Esophageal DNA Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542190?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:47","pubTimestamp":1785934049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420X1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855690","title":"Lucid Diagnostics to Present at Needham, Canaccord Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855690","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656855690?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:37","pubTimestamp":1785847024,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics to present at Needham, Canaccord investor conferencesLucid Diagnostics, a PAVmed subsidiary, scheduled management meetings at the Needham Virtual MedTech & Diagnostics 1x1 Conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9wVzL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656255666","title":"Lucid Diagnostics Management Participates in Canaccord Genuity Growth Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2656255666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656255666?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:32","pubTimestamp":1785846758,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics management participates in Canaccord Genuity Growth Conference fireside chatLucid Diagnostics management will attend the Needham Virtual MedTech & Diagnostics 1x1 Conference for meet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9hZq2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655774178","title":"Lucid Diagnostics Schedules Business Update Call to Discuss Q2 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655774178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655774178?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:33","pubTimestamp":1785414787,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics schedules business update call to discuss Q2 2026 resultsLucid Diagnostics scheduled a second-quarter 2026 business update conference call for Aug. 13, 2026 at 8:30 a.m. ET.Managemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL7sbXV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUCD","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646849073","title":"Lucid Diagnostics Shareholders Approve Stock Authorization Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2646849073","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646849073?lang=en_us&edition=fundamental","pubTime":"2026-06-25 05:32","pubTimestamp":1782336730,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On June 24, 2026, Lucid Diagnostics Inc. held its annual meeting of stockholders, with approx...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-shareholders-approve-stock-authorization-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-shareholders-approve-stock-authorization-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LCIZ","BK4551","BK4099","LCID","LCDL","BK4555","LUCD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646849823","title":"Lucid Diagnostics Shareholders Approve Charter Amendment Raising Authorized Common Shares to 400 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646849823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646849823?lang=en_us&edition=fundamental","pubTime":"2026-06-25 05:01","pubTimestamp":1782334878,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics shareholders approve charter amendment raising authorized common shares to 400 millionLucid Diagnostics held its annual shareholder meeting on June 24, 2026.Shareholders backed an am","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3FrwyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","PAVM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035499","title":"Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035499","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637035499?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:20","pubTimestamp":1779394856,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics director Dennis Matheis bought 245,000 common shares at a weighted average price of $1.Holdings rose to 1,033,443 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8KFLjX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081240","title":"PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081240","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081240?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:03","pubTimestamp":1778846597,"startTime":"0","endTime":"0","summary":"PAVmed posted a GAAP net loss attributable to common stockholders of USD 7 million, or USD 4.42 per diluted share, while operating expenses increased to USD 8.1 million.Revenue rose to USD 22,000, while cash and cash equivalents climbed to USD 6.5 million as of March 31, 2026.Veris Health advanced development of its implantable physiological monitor toward a planned FDA 510 submission, with presubmission and testing activities expected to begin soon.Lucid Diagnostics recognized USD 1.3 million of EsoGuard revenue on 3,177 tests, while its underwritten common stock offering netted about USD 17 million in proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLbyCcN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081284","title":"Press Release: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081284?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846400,"startTime":"0","endTime":"0","summary":"Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission. Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones. PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing. Conference call and webcast to be held today, May 15, at 8:30 AM EDT. NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and reported financial results for the first quarter ended March 31, 2026.The webcast will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","LUCD","PAVM","R","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712335","title":"Press Release: Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712335?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"Processed 3,177 EsoGuard tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones. Conference call and webcast to be held today, May 14, at 8:30 AM EDT. NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.   a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.  , today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026.The webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to jo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4082","LUCD","LCID","BK4232","BK4022","LCDL","R","LCIZ","BK4551","BK4555","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635128087","title":"Lucid Diagnostics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635128087","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635128087?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:59","pubTimestamp":1778759996,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc reports results for the quarter ended March 31 - Earnings SummaryLucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 17 cents per share for the quarter ended Marc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711155","title":"Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711155?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:20","pubTimestamp":1778757633,"startTime":"0","endTime":"0","summary":"In a report released today, Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on Lucid Diagnostics, with a price target of $3.00. Miks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LUCD","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635755562","title":"Lucid Diagnostics Q1 FY26 net loss widens to $13.9 million; revenue rises to $1.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635755562","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635755562?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:33","pubTimestamp":1778704427,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics posted a net loss of about USD 13.9 million for the quarter ended March 31, 2026, as revenue rose 62.5% to about USD 1.3 million.Sales and marketing expense climbed to about USD 5 million from USD 4.1 million a year earlier, while general and administrative expense fell to about USD 5.4 million from USD 6.2 million.Research and development expense edged down to about USD 1.2 million from USD 1.4 million, while other expense included a roughly USD 1.8 million increase in fair value of 2024 Convertible Notes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL9scRBg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634521848","title":"Lucid Diagnostics Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634521848","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634521848?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:01","pubTimestamp":1778583679,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc  expected to post a loss of8cents a share - Earnings Preview Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to  show a rise in quarterly revenue when it reports  results on May","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631632026","title":"Lucid Diagnostics to host business update call, report first-quarter results","url":"https://stock-news.laohu8.com/highlight/detail?id=2631632026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631632026?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:36","pubTimestamp":1777552609,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics will host a first-quarter 2026 business update conference call on May 14, 2026 at 8:30 a.m. ET.Chief executive Lishan Aklog will outline operations and growth strategy during call.CFO Dennis McGrath will review first-quarter 2026 financial results.Webcast will be available via investor relations site at luciddx.com.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL36yGm7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630787877","title":"Lucid Diagnostics Raises Capital Through Direct Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2630787877","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630787877?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:47","pubTimestamp":1777067247,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has shared an update. On April 24, 2026, Lucid Diagnostics closed an underwritten registered direct offering of 18,00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-raises-capital-through-direct-share-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-raises-capital-through-direct-share-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","LCIZ","LUCD","BK4596","LCDL","LCID","BK4555","BK4082","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840972","title":"Lucid Diagnostics closes USD 18 million follow-on offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840972","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629840972?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:27","pubTimestamp":1777040876,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics closed an underwritten registered direct offering of 18,000,000 common shares at USD 1 per share.Gross proceeds totaled about USD 18 million, including a USD 15 million anchor investment from a fundamental institutional investor.Net proceeds earmarked for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL7lNzqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629184066","title":"Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629184066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629184066?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:23","pubTimestamp":1777040638,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nTUA61W3DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629545438","title":"BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2629545438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629545438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 01:44","pubTimestamp":1776966278,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, United Rentals, cannabis stocks Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL6N4160QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADBE","CRWD","LUCD","LULU","LULG","AALG","AAL","ASGN","LRCX","ELMT","WST","NOW","MSFT","LMT","SIRI","PCG","TXN","CRSH","IBM","HON","CSX","CMCSA","HAS","INTU","KREF","MCHP","RNA","NEE","HLX","AXP","KDP","INTC","HELE","ROP","07766","TSLA","MBLY","QS","NFLX","REGN","PSKY","ON","ADI","TMO","FCX","NXPI","EFOR","ALT","APLD","APLZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":0.0886},{"period":"1month","weight":-0.0741},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.1803},{"period":"1year","weight":0},{"period":"ytd","weight":-0.0826}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.035074},{"month":2,"riseRate":0.8,"avgChangeRate":0.165426},{"month":3,"riseRate":0.4,"avgChangeRate":-0.121674},{"month":4,"riseRate":0.4,"avgChangeRate":-0.088036},{"month":5,"riseRate":0.4,"avgChangeRate":0.027971},{"month":6,"riseRate":0.4,"avgChangeRate":-0.052518},{"month":7,"riseRate":0.4,"avgChangeRate":-0.01165},{"month":8,"riseRate":0.8,"avgChangeRate":0.055824},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154424}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction